Treatment with SGLT2 inhibitors in patients with T2D and CKD is also associated with a reduced incidence of CV death (HR 0.84; 95% CI 0.74–0.96) (36, 38), the single major cause of death in this setting. This evidence concerns the gene SLC5A2 and chronic kidney disease.